Kalbe Farma and Kimia Farma to open raw materials plants in Indonesia
Indonesia is poised to become a production base for overseas and local manufacturers of medicines.
Vidjongtius, director of Indonesia's largest pharmaceutical company, Kalbe Farma, stated that raw material import is a big challenge for the local pharmacy industry. As a response, he declared, Kalbe Farma is currently constructing a biopharmacy raw material manufacturing plant in Cikarang, West Java, scheduled to commercially commence operations in late 2017 or 2018.
State-controlled pharmaceutical company Kimia Farma also announced recently that it would start constructing a Rp 100 billion raw materials plant in Cikarang, West Java, in 2016.
Meanwhile, in a bid to encourage the industry, the Investment Coordinating Board (BKPM) gauged a plan to allow foreign investors to hold more shares in pharmacy companies, from currently a maximum of 85%, to 100%.
Indonesia is indeed poised to become a production base for overseas and local manufacturers of medicines, including toll manufacturing.
Tailored to suit this fast changing industry, the 5th edition of CPHI South East Asia taking place during 6-8 April 2016 in Jakarta provides the must-attend trade exhibition where the regional pharma industry meets to leverage connections, knowledge and insight to spur business.
In December last year, Coordinating Economic Minister Darmin Nasution declared that the government was "not smart" if it did not support the growth of the pharmacy industry.
However, Maybank analyst Janni Asman commented that the removal of industry protection is likely to tighten the competition and lead to capped pricing power of local producers, "Most listed local pharmaceuticals are relatively less efficient than major generic producers in India and China," Janni wrote in her research.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance